5 Stocks Pushing The Health Care Sector Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 32 points (0.2%) at 14,286 as of Wednesday, March 6, 2013, 11:50 AM ET. The NYSE advances/declines ratio sits at 1,509 issues advancing vs. 1,334 declining with 158 unchanged.

The Health Care sector currently sits up 0.3% versus the S&P 500, which is up 0.1%. Top gainers within the sector include Vertex Pharmaceuticals ( VRTX), up 2.2%, Aetna ( AET), up 1.9%, Celgene Corporation ( CELG), up 1.6%, Teva Pharmaceutical Industries ( TEVA), up 1.4% and Regeneron Pharmaceuticals ( REGN), up 0.8%.

TheStreet Ratings group would like to highlight 5 stocks pushing the sector higher today:

5. Pharmacyclics Incorporated ( PCYC) is one of the companies pushing the Health Care sector higher today. As of noon trading, Pharmacyclics Incorporated is up $2.24 (2.4%) to $95.00 on average volume Thus far, 421,751 shares of Pharmacyclics Incorporated exchanged hands as compared to its average daily volume of 632,100 shares. The stock has ranged in price between $92.81-$95.85 after having opened the day at $93.00 as compared to the previous trading day's close of $92.76.

Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. Pharmacyclics Incorporated has a market cap of $6.4 billion and is part of the drugs industry. The company has a P/E ratio of 73.2, above the S&P 500 P/E ratio of 17.7. Shares are up 60.5% year to date as of the close of trading on Tuesday. Currently there are 4 analysts that rate Pharmacyclics Incorporated a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Pharmacyclics Incorporated as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pharmacyclics Incorporated Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

4. As of noon trading, Covidien ( COV) is up $0.76 (1.2%) to $65.47 on average volume Thus far, 1.2 million shares of Covidien exchanged hands as compared to its average daily volume of 2.2 million shares. The stock has ranged in price between $64.87-$65.58 after having opened the day at $65.00 as compared to the previous trading day's close of $64.71.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Covidien has a market cap of $30.2 billion and is part of the health services industry. The company has a P/E ratio of 16.3, below the S&P 500 P/E ratio of 17.7. Shares are up 12.1% year to date as of the close of trading on Tuesday. Currently there are 15 analysts that rate Covidien a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, attractive valuation levels, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Covidien Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

3. As of noon trading, Boston Scientific ( BSX) is up $0.14 (1.9%) to $7.52 on average volume Thus far, 10.9 million shares of Boston Scientific exchanged hands as compared to its average daily volume of 20.2 million shares. The stock has ranged in price between $7.35-$7.58 after having opened the day at $7.43 as compared to the previous trading day's close of $7.38.

Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. Boston Scientific has a market cap of $10.0 billion and is part of the health services industry. Shares are up 28.8% year to date as of the close of trading on Tuesday. Currently there are 4 analysts that rate Boston Scientific a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Boston Scientific as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and feeble growth in its earnings per share. Get the full Boston Scientific Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

2. As of noon trading, Agilent Technologies ( A) is up $0.50 (1.2%) to $43.16 on light volume Thus far, 1.3 million shares of Agilent Technologies exchanged hands as compared to its average daily volume of 3.5 million shares. The stock has ranged in price between $42.90-$43.32 after having opened the day at $43.00 as compared to the previous trading day's close of $42.66.

Agilent Technologies, Inc. provides bio-analytical and electronic measurement solutions and services to the life sciences, chemical analysis, diagnostics and genomics, communications, and electronics industries worldwide. Agilent Technologies has a market cap of $14.6 billion and is part of the health services industry. The company has a P/E ratio of 13.4, below the S&P 500 P/E ratio of 17.7. Shares are up 4.2% year to date as of the close of trading on Tuesday. Currently there are 13 analysts that rate Agilent Technologies a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Agilent Technologies as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Agilent Technologies Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

1. As of noon trading, Alexion Pharmaceuticals ( ALXN) is up $1.67 (1.8%) to $92.68 on average volume Thus far, 677,061 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $91.00-$92.90 after having opened the day at $91.21 as compared to the previous trading day's close of $91.01.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $17.5 billion and is part of the drugs industry. The company has a P/E ratio of 70.2, above the S&P 500 P/E ratio of 17.7. Shares are down 4.1% year to date as of the close of trading on Tuesday. Currently there are 16 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Alexion Pharmaceuticals Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

More from Markets

Dow Trades Higher, Nasdaq Slides as Chipmakers Fall

Dow Trades Higher, Nasdaq Slides as Chipmakers Fall

What Is Vertical Integration and What Are The Benefits?

What Is Vertical Integration and What Are The Benefits?

11 Investing Lessons Jim Cramer Has Learned This Year

11 Investing Lessons Jim Cramer Has Learned This Year

Stocks Destined for a Plunge so Don't Let Thursday's Epic Dow Rally Fool You

Stocks Destined for a Plunge so Don't Let Thursday's Epic Dow Rally Fool You

Elon Musk Tells New York Times Tweet Was Attempt at Transparency

Elon Musk Tells New York Times Tweet Was Attempt at Transparency